|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.38 USD | +0.03% |
|
-.--% | +0.22% |
| 01-08 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2000 Value Benchmark | CI |
| 01-08 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2500 Value Benchmark | CI |
| Market Cap | 6.96B 6.08B 5.59B 5.21B 9.88B 663B 10.03B 67.12B 26.09B 326B 26.12B 25.56B 1,122B | P/E 2023 |
-3.03x | P/E 2024 | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 6.77B 5.92B 5.44B 5.07B 9.62B 645B 9.77B 65.32B 25.39B 317B 25.42B 24.88B 1,092B | EV / Sales 2023 |
0.64x | EV / Sales 2024 | 84.5x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: Cidara Therapeutics
| 1 day | +0.03% | ||
| 6 months | +0.16% | ||
| Current year | +0.22% |
| Current year | 220.47 |  | 221.42 |
| 1 year | 45.59 | | 221.42 |
| 3 years | 10 | | 221.42 |
| 5 years | 8 | | 221.42 |
| 10 years | 8 | | 259 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Karbe
DFI | Director of Finance/CFO | 58 | 2025-02-23 |
Corrina Pavetto
CTO | Chief Tech/Sci/R&D Officer | - | 2025-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2025-04-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01-06 | Issuer sale | Director | 41,100 | 0.1621% | ||
| 01-06 | Issuer sale | Director | 42,920 | 0.1693% | ||
| 01-06 | Issuer sale | Director | 35,390 | 0.1396% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 63.9M 55.87M 51.34M 47.86M 90.77M 6.08B 92.14M 616M 240M 2.99B 240M 235M 10.31B | 1.28M 1.11M 1.02M 955K 1.81M 121M 1.84M 12.3M 4.78M 59.67M 4.79M 4.68M 206M |
| Net income | -22.93M -20.05M -18.42M -17.17M -32.57M -2.18B -33.06M -221M -85.98M -1.07B -86.07M -84.23M -3.7B | -170M -148M -136M -127M -241M -16.17B -245M -1.64B -637M -7.95B -637M -624M -27.39B |
| Net Debt | -30.9M -27.01M -24.83M -23.14M -43.89M -2.94B -44.56M -298M -116M -1.45B -116M -113M -4.98B | -186M -163M -150M -139M -265M -17.73B -269M -1.8B -698M -8.72B -699M -684M -30.04B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CDTX Stock
Select your edition
All financial news and data tailored to specific country editions
